Patents by Inventor Erwan BOURLES

Erwan BOURLES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation
    Patent number: 11590243
    Abstract: The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 28, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Erwan Bourles, Olivier Despas, Delphine Guillaume, Frederic Mathot, Mathieu Vasselle
  • Dried composition
    Patent number: 10973900
    Abstract: A composition dried under reduced pressure from a liquid mixture comprising: an adjuvant which comprises a TLR-4 agonist and a saponin in a liposomal formulation, wherein the liposomes contain a neutral lipid and a sterol, amorphous sugar, wherein the amorphous sugar is present in an amount of more than 7.5% (w/v) of the liquid mixture, and an antigen derived from Mycobacterium tuberculosis.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Vanessa Jully, Erwan Bourles
  • Pharmaceutical composition comprising an adenoviral vector
    Patent number: 10722470
    Abstract: The present invention relates to the formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: July 28, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Erwan Bourles, Frederic Mathot
  • DRIED COMPOSITION
    Publication number: 20200188499
    Abstract: A composition dried under reduced pressure from a liquid mixture comprising: an adjuvant which comprises a TLR-4 agonist and a saponin in a liposomal formulation, wherein the liposomes contain a neutral lipid and a sterol, amorphous sugar, wherein the amorphous sugar is present in an amount of more than 7.5% (w/v) of the liquid mixture, and an antigen derived from Mycobacterium tuberculosis.
    Type: Application
    Filed: May 11, 2018
    Publication date: June 18, 2020
    Inventors: Vanessa JULLY, Erwan BOURLES
  • NOVEL FORMULATION
    Publication number: 20190365930
    Abstract: The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 5, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Erwan BOURLES, Olivier DESPAS, Delphine GUILLAUME, Frederic MATHOT, Mathieu VASSELLE
  • PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOVIRAL VECTOR
    Publication number: 20180214379
    Abstract: The present invention relates to the formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.
    Type: Application
    Filed: July 20, 2016
    Publication date: August 2, 2018
    Applicant: GlaxoSmithKline Biologicals, S.A.
    Inventors: Erwan BOURLES, Frederic MATHOT